Studies of anti-IL-6R agents, such as tocilizumab [14–21] and sarilumab [22–24], in the treatment of moderate-to-severe RA have revealed the benefits of IL-6 inhibition, not only in the reduction of disease activity, but also improvement in pain and mood disorders associated with RA. Here, IL6R is linked to rheumatoid arthritis.